Attenuation of rubella virus by serial passage in primary rabbit kidney cell cultures

1967 ◽  
Vol 21 (2) ◽  
pp. 133-143 ◽  
Author(s):  
J. Peetermans ◽  
C. Huygelen
Keyword(s):  
Cell Cultures ◽  
Kidney Cell ◽  
Rubella Virus ◽  
Serial Passage ◽  
Rabbit Kidney ◽  
Primary Rabbit ◽  
Rabbit Kidney Cell

scholarly journals Trials with a live attenuated rubella virus vaccine, Cendehill strain

1970 ◽  
Vol 68 (3) ◽  
pp. 505-510 ◽  
Author(s):  
L. Grant ◽  
E. A. Belle ◽  
G. Provan ◽  
S. D. King ◽  
M. M. Sigel
Keyword(s):  
Children And Adolescents ◽  
Cell Cultures ◽  
Virus Vaccine ◽  
Kidney Cell ◽  
Rubella Virus ◽  
Close Contact ◽  
Rabbit Kidney ◽  
Primary Rabbit ◽  
Rabbit Kidney Cell ◽  
Female Subjects

SUMMARYThis report summarizes closed, family, and open studies conducted sequentially over a 10 month period with the Cendehill rubella virus vaccine in more than 16,000 children and adolescents. This strain of rubella was attenuated by serial propagation on primary rabbit kidney cell cultures. Inoculation of the Cendehill vaccine produced seroconversion in 97% of the 3589 susceptible (seronegative) vaccinated persons. There was no spread of the virus to susceptible controls living in close contact with those vaccinated. The vaccine was well tolerated. No arthritis or arthralgia occurred in 860 female subjects 13–18 years of age who were included in the study. The Cendehill vaccine would appear to meet the requirements of an acceptable vaccine.

THE CONTROL OF RUBELLA

PEDIATRICS ◽  
1969 ◽  
Vol 44 (1) ◽  
pp. 5-23
Author(s):  
Harry M. Meyer ◽  
Paul D. Parkman ◽  
Hope E. Hopps
Keyword(s):  
Cell Cultures ◽  
Kidney Cell ◽  
Rubella Virus ◽  
The United States ◽  
Embryo Cell ◽  
Rabbit Kidney ◽  
Adult Women ◽  
African Green Monkey Kidney ◽  
Attenuated Virus ◽  
Primary Rabbit

An attenuated strain of rubella virus was established by passage of the virus in primary African green monkey kidney cell cultures (GMK). In the first rubella vaccine clinical trial with seventy-seventh passage GMK material, none of eight inoculated children evidenced rubella-like illness and all developed antibody. The vaccine-induced infections were not transmitted to intimate contacts. Trials with large numbers of children confirmed the early findings of safety and immunogenicity of the vaccine. The second successfully attenuated virus, the Benoit strain, was developed by Hilleman and co-workers by adapting low GMK passages of virus to duck embryo cell cultures (DE). The Benoit strain, tested at several levels of tissue culture passage, designated A, B, C, D, and E, served as a clear demonstration of how rubella virus is modified by passage in mammalian or avian cells. Vaccines prepared from A and B level materials were not suitable, since they were either communicable or produced rubella-like symptoms. The C and D level materials were attenuated, but the higher passaged E level vaccine was termed "over-attenuated" since it induced antibody in only 60% of the vaccinees. More recently, the Cendehill strain, attenuated in primary rabbit kidney cell cultures (RK) and the RA 27/3 strain, attenuated in WI-38 cells, have been tested clinically. Vaccines which are now being produced by biologics manufacturers and considered candidates for license in the United States are: the HPV-77 strain passed 5 times in DE(HPV-77, DE5); the HPV-77 strain passed 12 times in dog kidney (DK) cell cultures (HPV-77, DK12), and the Cendehill strain passed 4 times in GMK and 53 times in RK (Cendehill GMK 4, RK 53). With each of these vaccines, antibody was detected in 90 to 100% of recipients. Fully attenuated rubella virus vaccines have not produced significant clinical reactions in children. However, mild rubella-like symptoms have been observed in adult women receiving vaccine; transient rashes, lymphadenopathy, arthralgia, and arthritis have been observed. Since the risk of spread of attenuated virus to the fetus in vaccinated women cannot be readily determined, the use of the vaccine during pregnancy would be potentially hazardous. Intranasal challenge of HPV-77 vaccinees with natural rubella virus demonstrated that vaccine-induced antibodies were protective against the clinical and virologic manifestations of rubella. Observation of vaccinated children over a 3-year period has demonstrated little evidence of a decline in the antibodies.

HERPESVIRUS LATENT IN PRIMARY RABBIT KIDNEY-CELL CULTURES

The Lancet ◽  
1972 ◽  
Vol 300 (7783) ◽  
pp. 930
Author(s):  
H. Malherbe ◽  
M. Strickland-Cholmley
Keyword(s):  
Cell Cultures ◽  
Kidney Cell ◽  
Rabbit Kidney ◽  
Primary Rabbit ◽  
Rabbit Kidney Cell

Effect of puromycin, cycloheximide, and p-fluorophenylalanine on fibroma virus DNA replication

1970 ◽  
Vol 16 (12) ◽  
pp. 1369-1370 ◽  
Author(s):  
Barbara A. Maloney ◽  
H. C. Minocha
Keyword(s):  
Dna Replication ◽  
Dna Synthesis ◽  
Cell Cultures ◽  
Kidney Cell ◽  
Rabbit Kidney ◽  
Rabbit Kidney Cell

Puromycin (2 μg/ml), cycloheximide (3 μg/ml), and p-fluorophenylalanine (400 μg/ml) completely inhibited Shope fibroma virus DNA synthesis in secondary rabbit kidney cell cultures as determined by autoradiography. The inhibition was reversed when the drugs were removed from the cultures.

scholarly journals Isolation of the wild-type rubella virus in rabbit kidney cell line RC-IAL

2004 ◽  
Vol 40 (2) ◽  
pp. 69-73
Author(s):  
Cristina A. Figueiredo ◽  
Maria I. Oliveira ◽  
Ana M. S. Afonso ◽  
Márcia Theobaldo ◽  
Aurea S. Cruz ◽  
...  
Keyword(s):  
Cell Line ◽  
Kidney Cell ◽  
Rubella Virus ◽  
Rabbit Kidney ◽  
Kidney Cell Line ◽  
Wild Type ◽  
Rabbit Kidney Cell
Sign in / Sign up

Export Citation Format

Share Document